Companies › Vaxcyte
2 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 3, 1 Phase 1; Infectious disease, Vaccines; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VAX-31 (low dose) 31 valent pneumococcal conjugate vaccine | UNKNOWN | Phase 3 | Pneumococcal Disease; Pneumococcal Vaccines | Mar 2027 |
| VAX-A1 Vaccine | – | Phase 1 | Group A Streptococcal Infection | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07284654 | VAX-31 (low dose) | Phase 3 | Pneumococcal Disease | Infectious disease | Sep 2026 |
| NCT07425392 | VAX-31 (low dose) | Phase 3 | Pneumococcal Vaccines | Vaccines | Mar 2027 |
| NCT07365826 | VAX-31 (low dose) | Phase 3 | Pneumococcal Disease | Infectious disease | Mar 2027 |
| NCT07616934 | VAX-A1 | Phase 1 | Group A Streptococcal Infection | Infectious disease | Dec 2027 |
| NCT06720038 | VAX-31 (low dose) | Phase 2 | Pneumococcal Vaccines | Vaccines | Dec 2027 |
| NCT06720038 | VAX-31 (low dose) | Phase 2 | Pneumococcal Vaccines | Vaccines | Dec 2027 |
| NCT06720038 | VAX-31 (low dose) | Phase 2 | Pneumococcal Vaccines | Vaccines | Dec 2027 |
| NCT06720038 | VAX-31 (low dose) | Phase 2 | Pneumococcal Vaccines | Vaccines | Dec 2027 |
Cash and short-term investments of $1.3bn on 2026-09-30; operating cash outflow about $989m a year; runway about 16 months at that burn, to Jan 2028; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
General Oncology Gilead Sciences Iterum Therapeutics, International Colgate Palmolive Zhejiang Raygene Pharmaceuticals
Cellid Dynavax Technologies Guangzhou Patronus Biotech SK Bioscience Inventprise
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.